SI1554301T1 - VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE - Google Patents
VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGEInfo
- Publication number
- SI1554301T1 SI1554301T1 SI200331929T SI200331929T SI1554301T1 SI 1554301 T1 SI1554301 T1 SI 1554301T1 SI 200331929 T SI200331929 T SI 200331929T SI 200331929 T SI200331929 T SI 200331929T SI 1554301 T1 SI1554301 T1 SI 1554301T1
- Authority
- SI
- Slovenia
- Prior art keywords
- dengue
- common
- utr
- vaccine containing
- nucleotide deletion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37786002P | 2002-05-03 | 2002-05-03 | |
US43650002P | 2002-12-23 | 2002-12-23 | |
PCT/US2003/013279 WO2003092592A2 (en) | 2002-05-03 | 2003-04-25 | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1554301T1 true SI1554301T1 (sl) | 2011-01-31 |
Family
ID=29406814
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200331929T SI1554301T1 (sl) | 2002-05-03 | 2003-04-25 | VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE |
SI200332569T SI2338508T1 (sl) | 2002-05-03 | 2003-04-25 | Rekombinantni himerni virus denga rDEN3/4delta 30(ME), rDEN2/4delta30(ME) ali rDEN1/4delta30(ME), ki vsebuje delecijo 30 nukleotidov (delta30) v delu 3' neprevedene regije genoma denge tipa 4, pri čemer delecija 30 nukleotidov ustreza strukturi steblo-zanka TL2 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200332569T SI2338508T1 (sl) | 2002-05-03 | 2003-04-25 | Rekombinantni himerni virus denga rDEN3/4delta 30(ME), rDEN2/4delta30(ME) ali rDEN1/4delta30(ME), ki vsebuje delecijo 30 nukleotidov (delta30) v delu 3' neprevedene regije genoma denge tipa 4, pri čemer delecija 30 nukleotidov ustreza strukturi steblo-zanka TL2 |
Country Status (15)
Country | Link |
---|---|
US (7) | US7517531B2 (sl) |
EP (5) | EP2319532A1 (sl) |
JP (1) | JP4977811B2 (sl) |
AT (1) | ATE481982T1 (sl) |
BR (1) | BRPI0309631B1 (sl) |
CA (1) | CA2483653C (sl) |
CY (1) | CY1120558T1 (sl) |
DE (1) | DE60334310D1 (sl) |
DK (2) | DK2338508T3 (sl) |
ES (2) | ES2677348T3 (sl) |
HU (1) | HUE037330T2 (sl) |
PT (2) | PT1554301E (sl) |
SI (2) | SI1554301T1 (sl) |
TR (1) | TR201806655T4 (sl) |
WO (1) | WO2003092592A2 (sl) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2483653C (en) * | 2002-05-03 | 2014-10-28 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 |
CN103031279B (zh) | 2005-04-24 | 2015-11-18 | 赛诺菲巴斯德生物制药有限责任公司 | 重组黄病毒疫苗 |
JP4549224B2 (ja) * | 2005-04-25 | 2010-09-22 | 出光ユニテック株式会社 | 透明ポリプロピレン系樹脂シートの製造方法、透明ポリプロピレン系樹脂シート、及び成形品、並びに透明ポリプロピレン系樹脂シートからなる成形品の白化防止方法、及び温度判別方法 |
WO2006134443A1 (en) * | 2005-06-17 | 2006-12-21 | Sanofi Pasteur | Dengue serotype 2 attenuated strain |
KR101536612B1 (ko) * | 2005-06-17 | 2015-07-14 | 사노피 파스퇴르 | 약독화된 뎅기 혈청형 1 균주 |
WO2007015783A2 (en) * | 2005-07-22 | 2007-02-08 | Research Development Foundation | Attenuated strains of flaviviruses , and uses thereof |
AU2013263788B2 (en) * | 2006-08-15 | 2016-05-26 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The | Development of dengue virus vaccine components |
CA3004991C (en) * | 2006-08-15 | 2022-08-30 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of dengue virus vaccine components |
AU2016219680B2 (en) * | 2006-08-15 | 2018-08-09 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The | Development of dengue virus vaccine components |
JP5623786B2 (ja) | 2009-05-22 | 2014-11-12 | 三星ディスプレイ株式會社Samsung Display Co.,Ltd. | 薄膜蒸着装置 |
TWI472639B (zh) | 2009-05-22 | 2015-02-11 | Samsung Display Co Ltd | 薄膜沉積設備 |
KR101117719B1 (ko) * | 2009-06-24 | 2012-03-08 | 삼성모바일디스플레이주식회사 | 박막 증착 장치 |
JP5328726B2 (ja) | 2009-08-25 | 2013-10-30 | 三星ディスプレイ株式會社 | 薄膜蒸着装置及びこれを利用した有機発光ディスプレイ装置の製造方法 |
JP5677785B2 (ja) | 2009-08-27 | 2015-02-25 | 三星ディスプレイ株式會社Samsung Display Co.,Ltd. | 薄膜蒸着装置及びこれを利用した有機発光表示装置の製造方法 |
CA2770888C (en) * | 2009-08-31 | 2020-04-14 | Gen-Probe Incorporated | Dengue virus assay |
US8876975B2 (en) | 2009-10-19 | 2014-11-04 | Samsung Display Co., Ltd. | Thin film deposition apparatus |
KR101084184B1 (ko) | 2010-01-11 | 2011-11-17 | 삼성모바일디스플레이주식회사 | 박막 증착 장치 |
KR101174875B1 (ko) | 2010-01-14 | 2012-08-17 | 삼성디스플레이 주식회사 | 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치 |
KR101193186B1 (ko) | 2010-02-01 | 2012-10-19 | 삼성디스플레이 주식회사 | 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치 |
KR101156441B1 (ko) | 2010-03-11 | 2012-06-18 | 삼성모바일디스플레이주식회사 | 박막 증착 장치 |
KR101202348B1 (ko) | 2010-04-06 | 2012-11-16 | 삼성디스플레이 주식회사 | 박막 증착 장치 및 이를 이용한 유기 발광 표시 장치의 제조 방법 |
US8894458B2 (en) | 2010-04-28 | 2014-11-25 | Samsung Display Co., Ltd. | Thin film deposition apparatus, method of manufacturing organic light-emitting display device by using the apparatus, and organic light-emitting display device manufactured by using the method |
IT1400574B1 (it) | 2010-05-06 | 2013-06-14 | Freni Brembo Spa | Dispositivo di frenatura a disco per veicoli |
US8685649B2 (en) | 2010-06-10 | 2014-04-01 | The United States Of America As Represented By The Secretary Of The Navy | RT-LAMP assay for the detection of pan-serotype dengue virus |
KR101223723B1 (ko) | 2010-07-07 | 2013-01-18 | 삼성디스플레이 주식회사 | 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치 |
CA2812306A1 (en) * | 2010-10-01 | 2012-04-05 | University Of Rochester | Flavivirus domain iii vaccine |
KR101738531B1 (ko) | 2010-10-22 | 2017-05-23 | 삼성디스플레이 주식회사 | 유기 발광 디스플레이 장치의 제조 방법 및 이에 따라 제조된 유기 발광 디스플레이 장치 |
KR101723506B1 (ko) | 2010-10-22 | 2017-04-19 | 삼성디스플레이 주식회사 | 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법 |
KR20120045865A (ko) | 2010-11-01 | 2012-05-09 | 삼성모바일디스플레이주식회사 | 유기층 증착 장치 |
WO2012065105A2 (en) * | 2010-11-12 | 2012-05-18 | Thomas Monath | Chimeric flavivirus vaccines |
KR20120065789A (ko) | 2010-12-13 | 2012-06-21 | 삼성모바일디스플레이주식회사 | 유기층 증착 장치 |
KR101760897B1 (ko) | 2011-01-12 | 2017-07-25 | 삼성디스플레이 주식회사 | 증착원 및 이를 구비하는 유기막 증착 장치 |
KR101852517B1 (ko) | 2011-05-25 | 2018-04-27 | 삼성디스플레이 주식회사 | 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법 |
KR101840654B1 (ko) | 2011-05-25 | 2018-03-22 | 삼성디스플레이 주식회사 | 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법 |
KR101857249B1 (ko) | 2011-05-27 | 2018-05-14 | 삼성디스플레이 주식회사 | 패터닝 슬릿 시트 어셈블리, 유기막 증착 장치, 유기 발광 표시장치제조 방법 및 유기 발광 표시 장치 |
KR20130004830A (ko) | 2011-07-04 | 2013-01-14 | 삼성디스플레이 주식회사 | 유기층 증착 장치 및 이를 이용한 유기 발광 표시 장치의 제조 방법 |
KR101826068B1 (ko) | 2011-07-04 | 2018-02-07 | 삼성디스플레이 주식회사 | 유기층 증착 장치 |
KR102015872B1 (ko) | 2012-06-22 | 2019-10-22 | 삼성디스플레이 주식회사 | 유기층 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조 방법 및 이에 따라 제조된 유기 발광 디스플레이 장치 |
US8895028B2 (en) | 2012-07-20 | 2014-11-25 | Arbovax, Inc. | Methods and compositions for dengue virus 3 (DV3) infectious clone |
MX2015000446A (es) * | 2012-07-24 | 2015-03-12 | Sanofi Pasteur | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue. |
KR102081284B1 (ko) | 2013-04-18 | 2020-02-26 | 삼성디스플레이 주식회사 | 증착장치, 이를 이용한 유기발광 디스플레이 장치 제조 방법 및 유기발광 디스플레이 장치 |
CN105246506A (zh) * | 2013-06-21 | 2016-01-13 | 默沙东公司 | 登革病毒疫苗组合物及其使用方法 |
NO340722B1 (no) * | 2014-06-27 | 2017-06-06 | Norwegian Institute For Agricultural & Environmental Res | Transgene planter som uttrykker et rekombinant tetravalent kimært denguevirusantigen for å fremstille effektive vaksiner avledet derfra, samt transgent plastid, plantecelle og frø, rekombinant DNA molekyl, vektor, fremgangsmåter for fremstilling og anvendelse derav |
SG11201704942QA (en) | 2014-12-22 | 2017-07-28 | Merck Sharp & Dohme | Dengue virus vaccine compositions and methods of use thereof |
US10004795B2 (en) * | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
US11285202B2 (en) * | 2016-01-26 | 2022-03-29 | University Of South Carolina | Polymer-protein core-shell particles as effective vaccine delivery vehicles and treatments methods using the same |
JP2019511221A (ja) | 2016-03-11 | 2019-04-25 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 弱毒化された生ジカウイルスワクチン |
AU2017250696A1 (en) * | 2016-04-13 | 2018-11-22 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
WO2018129160A1 (en) | 2017-01-06 | 2018-07-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Live attenuated flavivirus vaccines and methods of using and making same |
CN111447947B (zh) | 2017-12-07 | 2024-01-12 | 默沙东有限责任公司 | 登革病毒疫苗组合物的制剂 |
US20210338794A1 (en) * | 2018-09-04 | 2021-11-04 | Board Of Regents, The University Of Texas System | Dna plasmid-launched live-attanuated vaccines for plus-sense singel stranded rna |
WO2021173597A1 (en) * | 2020-02-28 | 2021-09-02 | Merck Sharp & Dohme Corp. | Dengue serotype specific rt-pcr multiplex assay |
WO2023161715A1 (en) * | 2022-02-22 | 2023-08-31 | Futr Bio Ltda. | Next generation mrna vaccines |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU776638B2 (en) * | 1999-03-26 | 2004-09-16 | Walter Reed Army Institute Of Research | Adaptation of virus to vertebrate cells |
EP1159969A1 (fr) * | 2000-05-30 | 2001-12-05 | Aventis Pasteur | Vaccine composition |
ES2523168T3 (es) * | 2001-05-22 | 2014-11-21 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos |
CA2483653C (en) * | 2002-05-03 | 2014-10-28 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 |
CA3004991C (en) * | 2006-08-15 | 2022-08-30 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of dengue virus vaccine components |
-
2003
- 2003-04-25 CA CA2483653A patent/CA2483653C/en not_active Expired - Lifetime
- 2003-04-25 EP EP10177740A patent/EP2319532A1/en not_active Ceased
- 2003-04-25 ES ES10177735.7T patent/ES2677348T3/es not_active Expired - Lifetime
- 2003-04-25 HU HUE10177735A patent/HUE037330T2/hu unknown
- 2003-04-25 WO PCT/US2003/013279 patent/WO2003092592A2/en active Application Filing
- 2003-04-25 EP EP17155603.8A patent/EP3205352A1/en not_active Withdrawn
- 2003-04-25 EP EP20153909.5A patent/EP3763382A1/en active Pending
- 2003-04-25 AT AT03724319T patent/ATE481982T1/de active
- 2003-04-25 SI SI200331929T patent/SI1554301T1/sl unknown
- 2003-04-25 TR TR2018/06655T patent/TR201806655T4/tr unknown
- 2003-04-25 DK DK10177735.7T patent/DK2338508T3/en active
- 2003-04-25 SI SI200332569T patent/SI2338508T1/sl unknown
- 2003-04-25 ES ES03724319T patent/ES2355719T3/es not_active Expired - Lifetime
- 2003-04-25 DE DE60334310T patent/DE60334310D1/de not_active Expired - Lifetime
- 2003-04-25 JP JP2004500777A patent/JP4977811B2/ja not_active Expired - Lifetime
- 2003-04-25 EP EP03724319A patent/EP1554301B1/en not_active Expired - Lifetime
- 2003-04-25 PT PT03724319T patent/PT1554301E/pt unknown
- 2003-04-25 DK DK03724319.3T patent/DK1554301T3/da active
- 2003-04-25 BR BRPI0309631-9A patent/BRPI0309631B1/pt not_active IP Right Cessation
- 2003-04-25 PT PT101777357T patent/PT2338508T/pt unknown
- 2003-04-25 EP EP10177735.7A patent/EP2338508B1/en not_active Expired - Lifetime
-
2004
- 2004-10-21 US US10/970,640 patent/US7517531B2/en not_active Ceased
-
2009
- 2009-03-04 US US12/398,043 patent/US8075903B2/en not_active Ceased
-
2011
- 2011-11-28 US US13/305,639 patent/US9783787B2/en not_active Expired - Lifetime
-
2013
- 2013-05-17 US US13/896,384 patent/USRE46631E1/en active Active
- 2013-05-17 US US13/896,388 patent/USRE46641E1/en not_active Expired - Lifetime
-
2017
- 2017-09-20 US US15/710,672 patent/US10837003B2/en not_active Expired - Lifetime
-
2018
- 2018-05-14 CY CY20181100488T patent/CY1120558T1/el unknown
-
2020
- 2020-09-01 US US17/009,448 patent/US11753627B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1554301A4 (en) | TETRAVALENT DENGUE VACCINE WITH A BLACK 30 NUCLEOTIDE DELETION IN 3'-UTR OF DENGUE TYPES 1,2,3 AND 4, OR ANTIGEN CHIMERAL DENGUE VIRUSES 1,2,3 AND 4 | |
UA85536C2 (en) | Viral antigens | |
DE69830579D1 (de) | Chimäre impfstoffe gegen flaviviren | |
ZA200007403B (en) | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals. | |
ATE443143T1 (de) | Chimäre und/oder wachstumgehemmte flaviviren | |
IL145702A0 (en) | Recombination influenza viruses for vaccines and gene theraphy | |
MXPA02012443A (es) | Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos. | |
MX2007009628A (es) | Virus de acido ribonucleico en replicacion como vacunas. | |
HK1076835A1 (en) | Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter | |
WO2003023040A3 (en) | Vaccinia virus mva-e3l-knockout-mutants and use thereof | |
WO2002072803A3 (en) | Subgenomic replicons of the flavivirus dengue | |
AU5460900A (en) | Infectious cdna clone of gb virus b and uses thereof | |
WO2003037265A3 (en) | Method of treating viral infections | |
WO1999057284A3 (en) | Attenuated influenza viruses | |
ATE453708T1 (de) | Impfstoff gegen west nile virus | |
DK1074266T3 (da) | Levende svækkede bakterier til anvendelse i vaccine | |
NZ511168A (en) | Recombinant CELO virus and CELO virus DNA | |
CY1117369T1 (el) | Εμβολιο για τον δαγγειο πυρετο που περιεχει μια κοινη 30 νουκλεοτιδιων διαγραφη στην 3'-utr των τυπων 1 και 2 ιου του δαγγειου πυρετου | |
WO2002083896A3 (en) | Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same | |
MY145463A (en) | Flavivirus ns1 subunit vaccine |